Is leuprolide FDA-approved, and what does the research show?

What is leuprolide?

Leuprolide is a synthetic version of GnRH, more potent than the natural hormone and built from nine amino acids, a nonapeptide ¹. Leuprolide is a GnRH agonist ¹, a drug that switches the GnRH receptor on rather than blocking it.

Most products carry it as the acetate and Camcevi as the mesylate, two chemical forms of the same drug ³. The depot forms, the long-acting injections, are microspheres, tiny beads of a slowly dissolving polymer, mixed into a suspension before injection so the drug is released over weeks or months ¹. A non-depot injection under the skin also exists ⁶. Leuprolide is not active by mouth ¹.

Is leuprolide FDA-approved?

Yes. Leuprolide is an FDA-approved prescription medicine ¹, ⁵, ⁶, ⁴. Drugs@FDA, FDA's register of approved drug applications, listed 28 applications with leuprolide as an active ingredient on November 6, 2026, 22 of them with a marketed product ³. The first, Lupron injection, was approved on April 9, 1985 ². Drugs@FDA now lists that product as discontinued, with a Federal Register determination that it was not withdrawn for safety or effectiveness reasons ².

Lupron Depot, the long-acting form for prostate cancer, followed on January 26, 1989, and the children's form, Lupron Depot-Ped, on April 16, 1993 ⁷, ⁸. The gynecology form of Lupron Depot was approved on October 22, 1990 ⁹. Other approved products, Eligard, Fensolvi and Camcevi, carry their own labels ³. Eligard's label approves it for advanced prostate cancer, Camcevi's for adults with it, and Fensolvi's for central precocious puberty from age 2 ¹⁰, ¹¹, ¹². Ten generic applications, eight of them marketed, cover the non-depot injection as of November 6, 2026 ³.

The approved uses are specific. Lupron Depot is "indicated for the treatment of advanced prostate cancer" ¹. The gynecology label approves it for "management of endometriosis, including pain relief and reduction of endometriotic lesions," lesions being the patches of endometriosis, alone or with norethindrone acetate, a progestin, a hormone drug of the progesterone family, given alongside it ⁴. The same label approves it, with iron, for "the preoperative hematologic improvement of women with anemia caused by fibroids," that is, raising the blood count before fibroid surgery; fibroids are non-cancerous growths of the uterus ⁴.

Lupron Depot-Ped "is indicated for the treatment of pediatric patients with central precocious puberty" ⁵. The non-depot injection is approved "in the palliative treatment of advanced prostatic cancer," palliative meaning to relieve rather than cure ⁶.

Those are the uses the labels name. None of the four labels approves it for weight, muscle, longevity, wellness or athletic performance ¹, ⁵, ⁶, ⁴. Leuprolide is not a wellness, weight or performance peptide; its approved job is to switch the sex hormones off ¹, ⁵, ⁴. Every label is prescription-only: the depot labels say the drug must be given under a physician's supervision or by a healthcare professional, and the generic label is marked "Rx only" ¹, ⁵, ⁶. The route to it is a licensed clinician's prescription ¹, ⁶.

See the FDA status of every peptide, updated weekly.

How does leuprolide work?

Leuprolide works in two phases, and the second is the one that treats disease ¹. First it stimulates. The prostate label says that in humans it causes "an initial increase in circulating concentrations of luteinizing hormone (LH) and follicle stimulating hormone (FSH)" ¹. LH and FSH are the two pituitary hormones that drive the testes and ovaries. That brings a short rise in testosterone in men and in estrogen in premenopausal women ¹.

Then, given continuously, it suppresses ⁵. The children's label says the pituitary's GnRH receptors are downregulated, meaning the gland responds less, so LH and FSH fall ⁵. The testes' and ovaries' production of testosterone and estradiol is then suppressed ⁵.

In men, "testosterone is reduced to castrate concentrations" ¹, the level seen after surgical removal of the testes, and in premenopausal women estrogens fall to postmenopausal levels ¹. The label says these decreases occur within two to four weeks, and that castrate testosterone in prostate cancer patients has been shown for more than five years ¹. The effect is reversible when the drug is stopped ⁵.

Each approved use rests on that suppression ¹, ⁴, ⁵. The gynecology label says the drug "induces a hypoestrogenic state," a state of low estrogen ⁴. In children, LH, FSH and sex hormones are held at prepubertal levels ⁵. Ganirelix, a GnRH antagonist, blocks the same receptor without the first rise and has its own page.

What does the research show?

FDA has approved leuprolide on the trials each label describes, so its evidence level is "Approved for a use" ¹, ⁴, ⁵. One of the children's label's trials is also published as a journal article ⁵, ¹³. The label trials measured hormone suppression and the signs of each disease ¹, ⁵, ⁴. The prostate and children's label trials were open-label, meaning patients and doctors knew the treatment; the gynecology label's were mostly controlled ¹, ⁵, ⁴.

Studied in men with prostate cancer: an open-label, non-comparative study enrolled 56 men with stage D2 prostate adenocarcinoma, cancer that had spread, and no prior systemic treatment ¹. Two of the 56 withdrew before suppression began; of the other 54, 51 reached the castrate range within 30 days and all 54 within 66 days ¹. Tumor assessments showed "no progression" in 40 of 52 men assessed at week 12 and 42 of 50 at week 24 ¹.

In the study of the six-month depot form, 151 men with prostate cancer were followed for 48 weeks ¹. Of 148 men with a week-4 value, testosterone stayed at castrate levels through week 48 in an estimated 93.4 percent ¹. The 95 percent confidence interval, the range within which the true figure most likely lies, was 89.2 to 97.6 ¹. Mean testosterone rose from 435 to 608 ng/dL in the first week, then fell to 16 by week 4 ¹.

The one-month study's objectives were testosterone suppression, tumor response and safety ¹. The label calls these studies non-comparative, so they did not test leuprolide against surgery or another drug ¹.

Studied in women with endometriosis: in controlled studies, six months of monthly Lupron Depot was "comparable to danazol," an older hormone drug ⁴. It was comparable to danazol in relieving pelvic pain, painful periods, pain with sex, pelvic tenderness and induration, a hardening of the tissue ⁴. It was also comparable in shrinking endometriosis patches seen at laparoscopy, a keyhole look inside the abdomen ⁴. The label adds that "the clinical significance of a decrease in endometriotic lesions is not known" ⁴.

Periods stopped in 74 percent of the women on leuprolide after the first month and in 98 percent after the second ⁴. Normal cycles had returned in 95 percent of them by the third month after treatment, not counting women who became pregnant ⁴.

A randomized study of 106 women with endometriosis was double-blind, meaning neither they nor their doctors knew the treatment ⁴. It compared a year of leuprolide alone, in 51, with leuprolide plus norethindrone acetate, in 55 ⁴. The hormone is called add-back therapy because it gives back some of what the drug removes ⁴.

Painful periods were present in every woman at baseline and in 4 percent of each arm at the end ⁴. Bone mineral density is the mineral content of bone and a measure of its strength. At the lumbar spine, the lower back, it fell 6.3 percent at week 52 on leuprolide alone, against 1.0 percent with add-back ⁴.

Studied in women with anemia from fibroids: one controlled trial enrolled women by blood count ⁴. Entry needed a hematocrit, the share of blood that is red cells, of 30 percent or less, or a hemoglobin, the red cells' oxygen-carrying protein, of 10.2 g/dL or less ⁴. On leuprolide with iron, 75 percent of 104 women reached a hematocrit of 36 percent and a hemoglobin of 12 g/dL at week 12 ⁴. On iron alone, 49 percent of 98 women did ⁴.

Uterine volume fell by a quarter or more in 60 percent of the women on leuprolide ⁴. In a follow-up of 46 women from one fibroid trial, the uterus returned to pretreatment size in a mean of 8.3 months ⁴.

Studied in children with central precocious puberty: the pivotal study, the main study behind the approval, was open-label and treated 55 children, 49 girls and 6 boys ⁵. Treatment began at a mean age of 7 and lasted a mean of 4 years ⁵. LH measured after a stimulation test was suppressed to prepubertal levels in 96 percent by month 1 ⁵.

Of the children followed after treatment, 87.9 percent had pubertal LH levels six months after stopping ⁵. Of 40 children followed afterward, 33 reached final or near-final adult height, with a height score of minus 0.2, close to the average for their age ⁵. The girls' periods began at a mean age of 12.9 ⁵.

The three-month depot trial, published online in February 2012, randomized 84 children, half never treated before and half previously treated, to one of two depot strengths for six months ¹³, ⁵. Peak stimulated LH was suppressed from months 2 through 6 in 78.4 percent of the lower-strength arm and 95.2 percent of the higher ¹³. There were nine treatment failures, children whose stimulated LH was not held down, in the lower-strength arm and two in the higher ¹³. Growth rates, advancement of bone age, the maturity of the bones on an X-ray, and adverse events were similar in the two arms ¹³. The six-month form's study of 45 children, single-arm, one treated group with no comparison, suppressed LH at week 24 in 86.7 percent ⁵.

The labels and the trial above report no study of leuprolide in healthy adults, or for weight, muscle, aging or performance ¹³, ¹, ⁵, ⁶, ⁴. Each enrolled people with one of the four approved conditions ¹³, ¹, ⁵, ⁴.

What are the side effects?

Hot flashes lead in most adult trials; the prostate label marks them as an expected effect of decreased testosterone and the gynecology label as a possible effect of decreased estrogen ¹, ⁴. In the prostate label's one-month depot trial of 56 men, hot flashes or sweats were reported by 57.1 percent and general pain by 23.2 ¹. Gastrointestinal disorders and edema, swelling from fluid, were reported by 14.3 percent each, and urinary disorders by 12.5 ¹. In the six-month depot study of 151 men, hot flashes (the label's "hot flush") were reported by 58.9 percent, injection site pain by 19.2 and fatigue by 13.2 ¹. Decreased libido, impotence and testicular atrophy, shrinking of the testes, are listed as "the expected physiologic effect of decreased testosterone levels" ¹.

In 166 women with endometriosis on leuprolide, hot flashes or sweats were reported by 84 percent, against 29 percent of 31 on placebo and 57 percent of 136 on danazol ⁴. Headache was reported by 32 percent, vaginitis, inflammation of the vagina, by 28, and depression or emotional lability, mood swings, by 22 against 3 on placebo ⁴. In four fibroid studies, 166 women on leuprolide reported hot flashes at 73 percent, against 18 percent of 163 on placebo ⁴. In the add-back study, 18 percent of each arm stopped for adverse reactions, most often hot flashes and insomnia on leuprolide alone and hot flashes and emotional lability with add-back ⁴.

In children, injection site reactions including abscess, a pocket of pus, were reported by 9 percent in the label's one-month safety table of 421 children ⁵. In the three-month study of 84, injection site pain was reported by 20 percent ⁵. Emotional lability or altered mood was reported by 5 percent in the one-month table and 5 percent in the three-month study ⁵. In the six-month study of 45 children, injection site reactions were reported by 78 percent, headache by 33 and psychiatric events by 22 ⁵.

The warnings are the labels'. The prostate label warns of tumor flare, a brief worsening of the cancer's signs during the initial testosterone rise ¹. Testosterone rises "to approximately 50% above baseline during the first weeks," and "spinal cord compression may contribute to paralysis with or without fatal complications" ¹.

It warns that GnRH agonists "may lead to metabolic changes such as hyperglycemia, diabetes mellitus, and hyperlipidemia" ¹, that is, high blood sugar, diabetes and high blood fats. It also warns that "increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men" ¹, a myocardial infarction being a heart attack. The same label warns of QT prolongation, a heart rhythm change, and of convulsions, severe skin reactions and fetal harm ¹.

The gynecology label warns of loss of bone mineral density, as defined above, "some of which may not be reversible after stopping treatment," and limits treatment with add-back therapy to 12 months ⁴. The children's label warns of an initial rise in sex hormones with signs of puberty, including vaginal bleeding ⁵. It also warns of psychiatric events, convulsions, severe skin reactions and pseudotumor cerebri, raised pressure inside the skull ⁵.

The prostate label's post-marketing reports add mood swings and depression, with "very rare reports of suicidal ideation and attempt," suicidal ideation being thoughts of suicide, and non-alcoholic fatty liver disease ¹. They add anaphylactoid symptoms, a severe allergic-type reaction, or asthma-like symptoms, at "about 0.002%" ¹. The prostate and gynecology labels add pituitary apoplexy, a loss of blood supply to the pituitary gland, mostly within two weeks of the first dose ¹, ⁴.

The labels contraindicate leuprolide, meaning it must not be given, in anyone hypersensitive, that is allergic, to GnRH or a GnRH agonist ¹, ⁵, ⁴. The gynecology and children's labels contraindicate it in pregnancy ⁵, ⁴. The gynecology label also contraindicates it in undiagnosed abnormal uterine bleeding ⁴.

In sport

WADA, the World Anti-Doping Agency, prohibits leuprolide at all times on its 2026 list ¹⁴. It names it by its international name, leuprorelin, in section S2.2.1, "Testosterone-stimulating peptides in males," under "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin)" ¹⁴. Section S2 covers "peptide hormones, growth factors, related substances, and mimetics," prohibited in and out of competition ¹⁴.

What JumpstartMD offers

JumpstartMD does not prescribe leuprolide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.